Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas.

Neurologia medico-chirurgica - 15 Jul 2018

Abe Hideaki, Natsumeda Manabu, Kanemaru Yu, Watanabe Jun, Tsukamoto Yoshihiro, Okada Masayasu, Yoshimura Junichi, Oishi Makoto, Fujii Yukihiko

Abstract excerpt

Histone H3 mutations are frequently found in diffuse midline gliomas (DMGs), which include diffuse intrinsic pontine gliomas and thalamic gliomas. These tumors have dismal prognoses. Recent evidence suggests that one reason for the poor prognoses is that O6-methylguanine-DNA methyltransferase (MGMT) promoter frequently lacks methylation in DMGs. This review compares the epigenetic changes brought about by histone...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to DNA Modification Methylases

Share to DNA Repair Enzymes

Share to Glioblastoma

Share to Isocitrate Dehydrogenase

Share to Jumonji Domain-Containing Histone Demethylases

Share to Temozolomide

Source

Open in PubMed Open full text

Identifiers

PMID: 29848907
DOI: 10.2176/nmc.ra.2018-0044
PMCID: PMC6048353

Genes

MGMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas.PMID 29848907Read ↗

MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline GliomasSemantic proximity Read ↗

Epigenetic mechanisms and therapeutic advances in diffuse midline glioma (Review).Semantic proximity Read ↗

Epigenetic and Metabolic Changes in Diffuse Intrinsic Pontine GliomaSemantic proximity Read ↗

Epigenetic-Targeted Treatments for H3K27M-Mutant Midline Gliomas.Semantic proximity Read ↗

Histone H3K27M Mutation in Brain Tumors.Semantic proximity Read ↗

DNA Methylation and Histone Modification in Low-Grade Gliomas: Current Understanding and Potential Clinical TargetsSemantic proximity Read ↗

Transcriptomic and epigenetic profiling of ‘diffuse midline gliomas, H3 K27M-mutant’ discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial locationSemantic proximity Read ↗

Diffuse midline glioma treated with epigenetic agent-based immunotherapySemantic proximity Read ↗

[Diffuse midline glioma].Semantic proximity Read ↗

Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutantSemantic proximity Read ↗

The Significance of MGMT Promoter Methylation Status in Diffuse GliomaSemantic proximity Read ↗

Integrated analyses reveal two molecularly and clinically distinct subtypes of H3 K27M-mutant diffuse midline gliomas with prognostic significance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.